Syros Pharmaceuticals Stock EBITDA

SYRS Stock

USD 0.28 0.08 22.22%

Syros Pharmaceuticals fundamentals help investors to digest information that contributes to Syros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syros Stock. The fundamental analysis module provides a way to measure Syros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syros Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	-157.2 M	-149.3 M

EBITDA is likely to gain to about (149.3 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Syros Pharmaceuticals Company EBITDA Analysis

Syros Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Syros Pharmaceuticals EBITDA

(157.19 M)

Most of Syros Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Syros EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Syros Pharmaceuticals is extremely important. It helps to project a fair market value of Syros Stock properly, considering its historical fundamentals such as EBITDA. Since Syros Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Syros Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Syros Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.44	0.85	-0.47	-0.83	0.56	0.88	0.03	-0.16	0.86	0.18	0.85	0.99	0.59	0.74	0.68	0.83	0.86	0.82	0.85	0.95	0.22
Total Stockholder Equity	0.44		0.1	-0.13	0.08	-0.41	0.35	0.2	0.53	-0.06	0.07	0.09	0.46	-0.43	0.29	0.2	-0.03	0.02	0.21	0.59	0.4	0.2
Net Tangible Assets	0.85	0.1		-0.39	-0.93	0.77	0.76	0.15	-0.28	0.9	-0.2	0.86	0.86	0.78	0.74	0.58	0.83	0.95	0.7	0.6	0.78	0.05
Net Debt	-0.47	-0.13	-0.39		0.39	-0.26	-0.2	0.52	0.67	-0.46	-0.08	-0.27	-0.56	-0.43	0.02	0.23	-0.56	-0.33	-0.25	-0.49	-0.64	0.27
Retained Earnings	-0.83	0.08	-0.93	0.39		-0.89	-0.76	0.01	0.37	-0.97	-0.01	-0.89	-0.82	-0.91	-0.63	-0.61	-0.93	-0.99	-0.7	-0.59	-0.8	0.0
Accounts Payable	0.56	-0.41	0.77	-0.26	-0.89		0.54	-0.01	-0.44	0.86	0.01	0.75	0.55	0.91	0.38	0.48	0.74	0.83	0.44	0.31	0.57	-0.21
Long Term Debt	0.88	0.35	0.76	-0.2	-0.76	0.54		0.31	0.07	0.77	0.03	0.94	0.85	0.49	0.8	0.76	0.66	0.79	0.78	0.67	0.79	0.3
Net Receivables	0.03	0.2	0.15	0.52	0.01	-0.01	0.31		0.66	-0.07	-0.55	0.22	0.01	-0.23	0.38	0.29	-0.29	0.04	0.04	-0.11	-0.09	0.09
Short Term Investments	-0.16	0.53	-0.28	0.67	0.37	-0.44	0.07	0.66		-0.47	-0.23	-0.15	-0.19	-0.64	0.04	0.14	-0.55	-0.29	-0.28	-0.05	-0.26	0.05
Total Liab	0.86	-0.06	0.9	-0.46	-0.97	0.86	0.77	-0.07	-0.47		0.12	0.9	0.85	0.9	0.66	0.64	0.95	0.96	0.8	0.64	0.84	0.12
Deferred Long Term Liab	0.18	0.07	-0.2	-0.08	-0.01	0.01	0.03	-0.55	-0.23	0.12		-0.05	0.11	0.02	-0.09	0.31	0.18	-0.03	0.22	0.2	0.2	0.22
Short Long Term Debt	0.85	0.09	0.86	-0.27	-0.89	0.75	0.94	0.22	-0.15	0.9	-0.05		0.83	0.72	0.77	0.72	0.79	0.9	0.77	0.63	0.79	0.2
Total Current Assets	0.99	0.46	0.86	-0.56	-0.82	0.55	0.85	0.01	-0.19	0.85	0.11	0.83		0.58	0.68	0.58	0.82	0.84	0.76	0.84	0.96	0.12
Short Term Debt	0.59	-0.43	0.78	-0.43	-0.91	0.91	0.49	-0.23	-0.64	0.9	0.02	0.72	0.58		0.38	0.4	0.88	0.86	0.53	0.35	0.59	-0.1
Common Stock	0.74	0.29	0.74	0.02	-0.63	0.38	0.8	0.38	0.04	0.66	-0.09	0.77	0.68	0.38		0.8	0.58	0.71	0.89	0.55	0.57	0.66
Property Plant Equipment	0.68	0.2	0.58	0.23	-0.61	0.48	0.76	0.29	0.14	0.64	0.31	0.72	0.58	0.4	0.8		0.5	0.66	0.76	0.47	0.51	0.53
Long Term Debt Total	0.83	-0.03	0.83	-0.56	-0.93	0.74	0.66	-0.29	-0.55	0.95	0.18	0.79	0.82	0.88	0.58	0.5		0.92	0.77	0.7	0.84	0.14
Capital Surpluse	0.86	0.02	0.95	-0.33	-0.99	0.83	0.79	0.04	-0.29	0.96	-0.03	0.9	0.84	0.86	0.71	0.66	0.92		0.74	0.65	0.8	0.09
Current Deferred Revenue	0.82	0.21	0.7	-0.25	-0.7	0.44	0.78	0.04	-0.28	0.8	0.22	0.77	0.76	0.53	0.89	0.76	0.77	0.74		0.68	0.73	0.67
Net Invested Capital	0.85	0.59	0.6	-0.49	-0.59	0.31	0.67	-0.11	-0.05	0.64	0.2	0.63	0.84	0.35	0.55	0.47	0.7	0.65	0.68		0.9	0.22
Net Working Capital	0.95	0.4	0.78	-0.64	-0.8	0.57	0.79	-0.09	-0.26	0.84	0.2	0.79	0.96	0.59	0.57	0.51	0.84	0.8	0.73	0.9		0.06
Capital Stock	0.22	0.2	0.05	0.27	0.0	-0.21	0.3	0.09	0.05	0.12	0.22	0.2	0.12	-0.1	0.66	0.53	0.14	0.09	0.67	0.22	0.06

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Syros Pharmaceuticals

Ebitda Over Time

Syros Ebitda

Ebitda

(149.34 Million)

At this time, Syros Pharmaceuticals' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Syros Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (157.19 Million). This is 117.92% lower than that of the Biotechnology sector and 256.95% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.03% higher than that of the company.

Syros EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syros Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syros Pharmaceuticals by comparing valuation metrics of similar companies.

Syros Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Syros Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Syros Pharmaceuticals from analyzing Syros Pharmaceuticals' financial statements. These drivers represent accounts that assess Syros Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syros Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	277.9M	499.7M	203.9M	45.3M	220.7M	141.1M
Enterprise Value	262.4M	391.9M	176.8M	(58.5M)	143.2M	99.6M

Syros Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Syros Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Syros Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Syros Pharmaceuticals' value.

		Shares
Blue Owl Capital Holdings Lp	2024-06-30	340.9 K
Walleye Trading Advisors, Llc	2024-06-30	285.8 K
Ubs O'connor Llc	2024-06-30	278.1 K
Exoduspoint Capital Management, Lp	2024-06-30	263.7 K
Goldman Sachs Group Inc	2024-06-30	262.4 K
Blackrock Inc	2024-06-30	259.2 K
Omega Fund Management Llc	2024-06-30	251.3 K
Geode Capital Management, Llc	2024-06-30	226.1 K
Marshall Wace Asset Management Ltd	2024-06-30	160.4 K
Bain Capital Life Sciences Investors, Llc	2024-06-30	2.7 M
Artal Group S A	2024-06-30	2.5 M

Syros Fundamentals

	Return On Equity	-7.77
	Return On Asset	-0.6
	Operating Margin	(288.92) %
	Current Valuation	9.33 M
	Shares Outstanding	26.83 M
	Shares Owned By Insiders	2.34 %
	Shares Owned By Institutions	81.05 %
	Number Of Shares Shorted	1.25 M
	Price To Earning	(7.92) X
	Price To Book	10.65 X
	Price To Sales	19.12 X
	Revenue	9.94 M
	Gross Profit	14.88 M
	EBITDA	(157.19 M)
	Net Income	(164.57 M)
	Cash And Equivalents	244.48 M
	Cash Per Share	12.09 X
	Total Debt	62.08 M
	Debt To Equity	0.49 %
	Current Ratio	6.57 X
	Book Value Per Share	(0.41) X
	Cash Flow From Operations	(109.71 M)
	Short Ratio	3.20 X
	Earnings Per Share	(3.07) X
	Target Price	1.0
	Number Of Employees	68
	Beta	1.59
	Market Capitalization	7.38 M
	Total Asset	168.17 M
	Retained Earnings	(722.81 M)
	Working Capital	108.3 M
	Current Asset	85.51 M
	Current Liabilities	9.57 M
	Net Asset	168.17 M

About Syros Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Syros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC